interferon alfa-1b
Trade name: Rebif
Recombinant proteinexperimental
Clinical trial activity
11 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
2
Phase 4
1
Earliest trial started Jan 1, 2001 (NCT00276536)
Timeline
Indications
Approved for
Studied for
- Breast Neoplasms · Phase 1
- COVID-19 · Phase 3
- Healthy Volunteers · Phase 1
- Hepatitis B · Phase 2
- Hepatitis B, Chronic · Phase 2
- Kidney Neoplasms · Phase 2
- Lymphoma · Phase 1
- Melanoma · Phase 1
- Multiple Myeloma · Phase 1
- Multiple Sclerosis · Phase 4
- Multiple Sclerosis, Relapsing-Remitting · Phase 3
- Neoplasms · Phase 3
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Respiratory Tract Infections · Phase 3
- Sarcoma · Phase 1
Mechanism of action
- Interferon alphaSupplementation
Interferon alpha supplementation
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSG7407IV2FS ↗
Also known as
- interferon alfa-1b
- nu100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06277167 | Phase 1 | Jan 7, 2023 | Kexing Biopharm Co., Ltd., The Third Hospital of Changsha |
| NCT05734807 | Phase 2 | Jul 20, 2022 | Huahui Health |
| NCT04878211 | Phase 4 | Jun 10, 2021 | Novartis |
| NCT04749368 | Phase 2 | Apr 12, 2021 | Brii Biosciences, VBI Vaccines Inc., Vir Biotechnology, Inc. |
| NCT04534725 | Phase 3 | Dec 17, 2020 | Peter MacCallum Cancer Centre |
| NCT04251871 | N/A | Jan 22, 2020 | People's Liberation Army of China |
| NCT04078399 | N/A | Aug 28, 2019 | Jiao Tong University |
| NCT04534634 | Phase 2 | Apr 1, 2019 | Soochow University |
| NCT01464905 | Phase 3 | Oct 1, 2011 | Nuron Biotech |
| NCT00278174 | Phase 2 | Feb 1, 2005 | Case Western Reserve University, National Cancer Institute (NCI), University of Rochester |
| NCT00276536 | Phase 1 | Jan 1, 2001 | National Cancer Institute (NCI), University of Rochester |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2001 |
| University of Rochester | Academic/Hospital | 2 | 1 | 2 | 2001 |
| Brii Biosciences | For profit | 1 | 1 | 1 | 2021 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Huahui Health | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Kexing Biopharm Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Novartis | For profit | 1 | 1 | 1 | 2021 |
| Nuron Biotech | For profit | 1 | 1 | 1 | 2011 |
| People's Liberation Army of China | Government | 1 | 1 | 1 | 2020 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Soochow University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| The Third Hospital of Changsha | Academic/Hospital | 1 | 0 | 1 | 2023 |
| VBI Vaccines Inc. | For profit | 1 | 0 | 1 | 2021 |
| Vir Biotechnology, Inc. | For profit | 1 | 0 | 1 | 2021 |
15 organizations
Page 1 / 1